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Erythropoietin (EPO) is a glycoprotein hormone that is the
primary regulator of erythropoiesis, maintaining the body’s red
blood cell mass at an optimum level (Krantz, 1991; Lacombe and
Mayeux, 1998). In response to a decrease in tissue oxygenation,
EPO synthesis increases in the kidney. The secreted hormone
binds to specific receptors on the surface of red blood cell pre-
cursors in the bone marrow, leading to their survival, proliferation
and differentiation, and ultimately to an increase in haematocrit
(D’Andrea et al, 1989; Lodish et al, 1995). 
Since its introduction more than a decade ago, recombinant
human EPO (rHuEPO) has become the standard of care in treating
the anaemia associated with chronic renal failure (CRF). It is
highly effective at correcting the anaemia, restoring energy levels,
and increasing patient well being and quality of life (Winearls
et al, 1986; Eschbach et al, 1987, 1989; Evans et al, 1990). It has
also been approved for the treatment of anaemia associated with
cancer, HIV infection, and use in the surgical setting to decrease
the need for allogeneic blood transfusions. For all indications, it
has proven to be remarkably well tolerated and highly efficacious
(Markham and Bryson, 1995; Cazzola et al, 1997; Sowade et al,
1998). 
The recommended and usual therapy with rHuEPO is 2 to 3
times per week by subcutaneous or intravenous injection. For CRF
patients, the duration of therapy is for the life of the patient, or
until a successful kidney transplant restores kidney function,
including the production of the natural hormone. For cancer
patients, rHuEPO therapy is indicated for as long as the anaemia
persists, generally through the entire course of chemotherapy. 
It can be a hardship to administer rHuEPO 2 to 3 times per
week, particularly for those patients who do not otherwise need to
be seen in the clinic this frequently. In these cases, the patient
needs to make a special trip to the clinic for his or her rHuEPO
therapy. As is true for all growth factors, reduction in dose
frequency results in a significant loss in efficiency. That is, the
total weekly dose required when rHuEPO is administered one time
per week is greater than when it is administered as 2 to 3 divided
doses. It was anticipated that this clinical need could be addressed
by creating a molecule with enhanced in vivo bioactivity to allow
for less frequent dosing of patients. 
To create a molecule with enhanced activity, research was
initially directed towards elucidating those factors and structural
features that control the in vivo activity of EPO (Egrie et al, 
1993). This research led to the discovery and development of
darbepoetin alfa, a novel erythropoiesis stimulating protein (NESP,
ARANESPTM, Amgen Inc, Thousand Oaks), that can be adminis-
tered less frequently than epoetin (Egrie et al, 1997). 
STRUCTURE OF EPO 
Human EPO is a 30 400 dalton heavily glycosylated protein
hormone (Miyake et al, 1977; Davis et al, 1987). Sixty percent (by
weight) of the molecule is an invariant 165 amino acid single
polypeptide chain containing 2 disulphide bonds (Lai et al, 1986;
Recny et al, 1987). The remaining 40% of the mass of the mole-
cule is carbohydrate. Carbohydrate addition (glycosylation) is a
post-translational event that results in the addition of sugar chains
to specific asparagine (N-linked) or serine/threonine (O-linked)
amino acids in the polypeptide. The carbohydrate portion of
natural and recombinant human EPO consists of 3 N-linked sugar
chains at Asn 24, 38 and 83, and one O-linked (mucin-type) sugar
chain at Ser 126 (Browne et al, 1986; Egrie et al, 1986). 
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This review article was supported by Amgen Inc, Thousand Oaks, California, USA. Structure determinations using nuclear magnetic resonance
(NMR) spectroscopy (Cheetham et al, 1998) and X-ray crystallog-
raphy (Syed et al, 1998) have indicated that human EPO is an
elongated molecule with an overall topology of a left-handed 
4-helix bundle, typical of members of the haematopoietic growth
factor family. In addition, these studies have identified the amino
acids at the receptor-binding sites. The carbohydrate addition sites
are clustered at one end of the molecule, distal from the receptor-
binding site. While the 4 carbohydrate chains contribute approxi-
mately 40% of the mass of the hormone, they probably cover
much of the surface of the molecule since they have an extended
and flexible molecular structure. 
In contrast to the invariant amino acid sequence of the protein
portion of glycoproteins, the carbohydrate structures are variable,
a feature referred to as microheterogeneity. For example,
N-glycosylation sites on the same protein may contain different
carbohydrate structures. Furthermore, even at the same glycosyla-
tion site on a given glycoprotein, different structures may be
found. This heterogeneity is a consequence of the non-template-
directed synthesis of carbohydrates. 
The carbohydrate structures of EPO have been determined and
the extent of the microheterogeneity defined for both rHuEPO and
the natural hormone (Sasaki et al, 1987, 1988; Takeuchi et al,
1988; Tsuda et al, 1988). One of the most prominent examples of
microheterogeneity for EPO is seen on the N-linked carbohydrate
chains, where the oligosaccharides may contain 2, 3 or 4 branches
(or antennae), each of which is typically terminated with the nega-
tively charged sugar molecule, sialic acid (Figure 1). With the
exception of sialic acid, all of the other sugar molecules on EPO
are neutral. Similarly, the single O-linked carbohydrate may
contain 0 to 2 sialic acid molecules. Since each of the 3 N-linked
oligosaccharides can contain up to 4 sialic acid residues, and the
single O-linked chain can contain 2, the EPO molecule can have a
maximum of 14 sialic acid residues. Therefore, because of the
variability in sugar structure, the number of sialic acid molecules
on EPO varies, and as a consequence, so does the molecule’s net
negative charge. As indicated in Figure 1, an isoform of EPO is
defined as a subset of the EPO molecules that has a defined charge
due to its sialic acid content. For reference, epoetin alfa
(EPOGEN®, Amgen Inc, Thousand Oaks, CA), the source of the
purified rHuEPO used for these studies, has been purified so as to
contain isoforms 9–14. 
ROLE OF CARBOHYDRATE IN BIOLOGICAL
ACTIVITY 
The carbohydrate portions of different glycoprotein molecules
have been shown to have many diverse functions, including effects
on the biosynthesis and secretion, immune protection, conforma-
tion, stability, solubility and biological activity of molecules
(Skehel et al, 1984; Cumming, 1991). For rHuEPO, in particular, it
has been shown that the addition of carbohydrate is required for
secretion from the cell, and for increasing the solubility of the
molecule (Dube et al, 1988; Narhi et al, 1991; Delorme et al,
1992). Early research on EPO from natural sources indicated that
the sialic acid residues were necessary for biological activity
in vivo (Lowry et al, 1960; Lukowsky and Painter, 1972;
Goldwasser et al, 1974). Removal of the sialic acid from either
native EPO or rHuEPO resulted in molecules having an increased
activity in vitro, but very low activity in vivo, presumably due to
removal from circulation by the asialoglycoprotein receptor in the
liver (Fukuda et al, 1989; Spivak and Hogans, 1989). Similarly, it
was shown that EPO molecules, which have been deglycosylated
to remove carbohydrate (or produced in E. coli to allow expression
of only the EPO polypeptide), are active in vitro, but have very
low in vivo activity (Dordal et al, 1985; Higuchi et al, 1992). 
In order to define further the role of carbohydrate in biological
activity, the approach taken was to purify EPO carbohydrate
isoforms, measure their in vivo activity and determine how the
different carbohydrate structures affect activity. 
RHuEPO, produced by Chinese hamster ovary cells, was puri-
fied to contain the entire complement of isoforms 4–14, and then
further fractionated by ion exchange chromatography to isolate the
individual isoforms (Egrie et al, 1993). The in vivo efficacy of
each of the individual isoforms was tested in normal mice to deter-
mine the effect of repetitive dosing on the haematocrit. In this
assay, CD-1 mice were injected with either a vehicle control or an
equimolar dose (2.5 mcg kg–1 of peptide) of each of the individual
isoforms by intraperitoneal injection 3 times per week for 1 month.
The results of this experiment demonstrated a striking difference
in the biological activity of the individual isoforms, with those
isoforms having a higher sialic acid content exhibiting a progres-
sively higher in vivo efficacy (Figure 2). By day 30, the group
mean haematocrit of isoform 14-treated animals increased by
26.2 ± 2.7 points (to a haematocrit of 76.2%), compared with an
increase of only 6.3 ± 3.5 points for the isoform 8-treated group, a
4.2-fold increase in efficacy. In contrast, animals receiving vehicle
control showed no haematocrit change from baseline during the
experiment. 
It was reasoned that these results might have 2 possible expla-
nations: the more active isoforms might have a longer serum half-
life and/or an increased ability to bind to the EPO receptor. In
order to assess the contribution of each of these possibilities, the
pharmacokinetics and receptor-binding activity of the individual
isoforms was measured. 
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Figure 1 Schematic of EPO carbohydrate structure and EPO isoform
designation The isolated EPO isoforms were iodinated and their circulating
half-life determined after intravenous injection into rats. At speci-
fied intervals after dosing, blood samples were taken and the frac-
tion of iodinated isoform remaining in circulation was measured.
The isoforms with the increased sialic acid content had a longer
serum half-life than those with the lower sialic acid content
(Figure 3). The beta half-life of isoform 14 was 3.2-fold longer
than that for isoform 6 (3.97 vs 1.24 hours, respectively). As
expected from these results, the serum clearance of the isoforms
progressively increased as the sialic acid content decreased. In
contrast, the volume of distribution was the same for the individual
isoforms and approximately equal to the plasma volume (data not
shown). Thus, those isoforms that have a higher sialic acid content
have a higher in vivo biological activity, longer serum half-life and
slower serum clearance. 
Next, the relative affinity of various EPO isoform preparations
for the EPO receptor was determined in a radioreceptor assay
(Broudy et al, 1988). This assay measures the quantity of each
isoform required to displace 125I-rHuEPO bound to the EPO
receptor on the surface of OCIM1 cells. The IC50, the amount of
test compound required to compete 50% of the receptor-bound
125I-rHuEPO, was determined for each isoform. As seen in Figure
3, the higher the sialic acid content, the greater the quantity of EPO
isoform necessary to compete 125l-rHuEPO binding. Thus, those
isoforms having a higher sialic acid content had a lower relative
affinity for the EPO receptor. The relative affinity of isoform 6 for
the EPO receptor was 7-fold greater than that for isoform 14. 
Taken together, these experiments indicate that the carbohydrate
moieties of EPO have significant effects on the biological activity
of the hormone, modulating both receptor affinity and serum clear-
ance. There is a direct relationship between sialic acid content,
in vivo biological activity, and serum half-life, but an inverse rela-
tionship with receptor affinity. While conventional wisdom might
have predicted that increases in receptor affinity would lead to a
more active molecule, clearly this is not the case. In fact, as shown
in these experiments, isoform 9, which has a 2.6-fold greater
affinity for the EPO receptor than isoform 14, has only approxi-
mately one-third of the in vivo activity (Figures 2 and 3). These
observations clearly demonstrate that clearance has a far stronger
influence on in vivo activity than does receptor-binding affinity.
Increases in serum half-life were able to overcome the observed
decreases in receptor affinity. Thus, for EPO, serum clearance, not
receptor-binding affinity, is the primary determinant of in vivo
activity. 
DESIGN OF HYPERGLYCOSYLATED RHuEPO
ANALOGUES 
In addition to identifying serum half-life as a major controlling
factor of the in vivo biological activity of EPO, these experiments
led to the hypothesis that increasing the sialic acid containing
carbohydrate of EPO would increase its serum half-life and
thereby the in vivo biological activity of the molecule. 
To test this hypothesis, additional N-linked carbohydrate chains
were added to the rHuEPO molecule. N-linked carbohydrate is
attached to the polypeptide backbone at a consensus sequence for
carbohydrate addition (Asn-XXX-Ser/Thr). To introduce new
carbohydrate attachment sites into the polypeptide backbone, the
DNA sequence of the cloned human EPO gene needed to be
modified to code for one or more new consensus sequences. The
consensus sequences needed to be added at positions that were
compatible with carbohydrate addition. While the consensus
Development and characterization of NESP 5
British Journal of Cancer (2001) 84(Supplement 1), 3–10 © 2001 Cancer Research Campaign
30
25
20
15
10
5
0
I
n
c
r
e
a
s
e
 
i
n
 
h
a
e
m
a
t
o
c
r
i
t
–
D
a
y
 
3
0
8 9 10 11 12 13 14
Isoform
Figure 2 In vivo efficacy of isolated EPO isoforms. CD-1 mice 
(n = 20/group) received an equimolar dose (2.5 mcg kg–1 of peptide) of each
of the isolated EPO isoforms or vehicle control 3 times per week for 30 days
by intraperitoneal injection. The haematocrit of each mouse was determined
at baseline and twice-weekly thereafter. At the conclusion of the study, final
serum samples from all mice were screened for anti-rHuEPO antibodies by a
radioimmunoprecipitation assay (Egrie et al, 1986). Mice that developed a
significant anti-rHuEPO antibody response were excluded from analysis. The
increase in haematocrit over baseline following 30 days of treatment (Day
30) was calculated for each mouse and the group average haematocrit
increase (± SD) calculated for each group. There was no significant change
in haematocrit in the vehicle control group over the course of the study 
(46.1% ± 1.2 vs 45.2% ± 1.2 for baseline and day 30, respectively) 
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Figure 3 EPO isoforms having a higher sialic acid content have a longer
serum half-life and a lower receptor binding activity. The serum half-life 
(solid bars) and receptor binding activity (hatched bars) were determined for
various isolated EPO isoform preparations. To determine serum half-life,
iodinated isoforms were administered intravenously into cannulated Sprague-
Dawley rats (n = 4/group). Blood samples were collected and the fraction of
ethanol-precipitable iodinated isoform remaining in the serum was measured.
The receptor binding activity of isolated EPO isoforms was measured using a
radioreceptor assay (Broudy et al, 1988). Increasing concentrations of each
unlabelled isolated EPO isoform were incubated with 0.5 ng of 125I-rHuEPO
(a mixture of isoforms 9–14) and OCIM1 cells. Cell receptor-bound 
125I-rHuEPO was measured following separation from unbound 125I-rHuEPO.
Linear regression analysis was used to calculate the IC50 (the concentration
of unlabelled EPO isoform required to compete 50% of the amount of 
125I-rHuEPO bound in the absence of cold competitor). The IC50 for unlabelled
rHuEPO was 0.54 ng sequence is necessary for carbohydrate addition, it is not sufficient
to ensure that a carbohydrate addition site will be utilized. Other
factors, such as the local protein folding and conformation during
biosynthesis, determine whether an oligosaccharide is attached
at a given consensus sequence site. In addition, the consensus
sequences needed to be added to positions that did not interfere
with receptor binding, or compromise the folding, conformation,
or stability of the molecule. 
At the time that these studies were initiated, there was only an
incomplete understanding of the 3-dimensional structure of EPO.
This understanding was largely gained through site-directed muta-
genesis studies where individual amino acids were changed and
the result of the change evaluated for effects on bioactivity and
conformation (Lin, 1987; Boissel and Bunn, 1990) These struc-
ture/function experiments identified many of the amino acids that
were critical for EPO receptor interaction and necessary for proper
folding of the molecule. Although these studies provided insight as
to which amino acids should not be altered, they did not allow
identification of positions where extra carbohydrate addition sites
could be added whilst maintaining structure. 
To test this hypothesis, several dozen analogues of rHuEPO
containing one or more amino acid substitutions, which created
one or more new carbohydrate addition sites, were produced
(Elliott et al, 2000). Site-directed mutagenesis was first used to
change the nucleic acid sequence encoding one or more amino
acids of a human EPO cDNA clone. Next, the clone encoding each
new candidate analogue was transfected into mammalian cells and
the expressed protein analysed. Only a few of the several dozen
analogues tested were fully glycosylated, had the proper tertiary
structure, and retained biological activity. The EPO analogues that
were properly glycosylated each had one extra N-linked carbohy-
drate chain (4-chain analogue). By combining the carbohydrate
addition sites of 2 successfully glycosylated 4-chain analogues
into one molecule, the 5 N-linked chain analogue, NESP, was
created. The amino acid sequence of NESP differs from that
of human EPO at 5 positions (Ala30Asn, His32Thr, Pro87Val,
Trp88Asn, and Pro90Thr) allowing for additional oligosaccharide
attachment at asparagine residues at positions 30 and 88 (Elliott
et al, 2000). 
Due to the additional carbohydrate, these 4 and 5 N-linked
(NESP) chain analogues are each biochemically distinct from
rHuEPO (Figure 4). They have an increased molecular weight,
sialic acid content and negative charge. Each additional N-linked
carbohydrate chain increases the molecular weight of the protein
by approximately 3300 daltons and adds up to 4 additional sialic
acid residues. Thus, in comparison with rHuEPO, the 2 extra
carbohydrate chains on NESP increase the molecular weight by
22% (to 37 100 daltons) and the maximum number of sialic acid
residues from 14 to 22. 
BIOLOGICAL ACTIVITY OF
HYPERGLYCOSYLATED rHuEPO ANALOGUES 
These analogues, having four and five N-linked carbohydrate
chains, were used to test the hypothesis that increasing the sialic
acid-containing carbohydrate content of EPO would increase the
serum half-life and thereby the in vivo bioactivity. 
The in vivo efficacy of rHuEPO, the 4-chain analogue, and
NESP (5-chain analogue) were compared by measuring the
increase in haematocrit of mice injected thrice-weekly with
equimolar doses (2.5 mcg kg–1 of peptide) of each molecule for 
6 weeks (Figure 5). Both NESP and the 4-chain analogue
produced a faster rate of haematocrit rise and a higher stable
plateau haematocrit than rHuEPO. By day 31 the haematocrit had
increased by 22.8 ± 2.3, 28.1 ± 6.8, and 33.9 ± 3.4 points for mice
treated with rHuEPO, 4-chain analogue, and NESP, respectively
and these haematocrit differences were maintained for the duration
of the experiment. Consistent with the hypothesis, the magnitude
of the haematocrit increase correlated with the number of carbo-
hydrate chains and the sialic acid content of the molecules. Thus,
by day 31, treatment with the 5-chain analogue, NESP, increased
the haematocrit 11 points more than rHuEPO, while the response
produced by the 4-chain analogue was intermediate between that
of NESP and rHuEPO. 
To confirm that the mechanism of increased activity was due to
an increase in the circulating half-life, the pharmacokinetics of
rHuEPO, the 4-chain analogue, and NESP were compared. As
seen in Figure 6, the greater the sialic acid-containing carbo-
hydrate content of the molecule, the longer its circulating half-life.
The beta half-life of both hyperglycosylated molecules was greater
than that determined for rHuEPO and for isoform 14, the highest
of the naturally-occurring EPO isoforms. In contrast, the volume
of distribution was equivalent for the 3 molecules and approxi-
mately equal to the plasma volume (data not shown). 
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Figure 4 Biochemical and biological properties of rHuEPO and rHuEPO analogues containing four and five N-linked carbohydrate chains (Egrie et al, 1997) RHuEPO, the 4-chain analogue, and NESP were tested for EPO
receptor-binding activity in the radioreceptor assay. Consistent
with the results obtained in this assay for the isolated isoforms and
the hypothesis, the relative EPO receptor-binding affinity was
inversely correlated with the carbohydrate content. The relative
affinity of NESP for the EPO receptor was 4.3-fold lower than that
of rHuEPO and significantly lower than that of isoform 14. The
results with the 4-chain analogue were intermediate between those
of NESP and rHuEPO (data not shown). 
These results confirm the hypothesis that the serum half-life 
of rHuEPO could be extended by increasing the sialic acid-
containing carbohydrate content beyond that found naturally, and
that the longer serum half-life would lead to an increase in in vivo
biological activity (Figure 4). The results with the 4- and 5-chain
hyperglycosylated EPO analogues were also consistent with the
previous observations that the increases in serum half-life more
than offset the decreases in receptor-binding affinity. The in vivo
biological activity of both the 4-chain analogue and NESP were
greater than that of rHuEPO even though they each had a lower
affinity for the EPO receptor. 
COMPARISON OF THE IN VIVO EFFICACY OF
NESP WITH RHuEPO 
To further characterize NESP and evaluate its potential as a thera-
peutic for human use, comparative pharmacodynamic studies of
NESP and rHuEPO were performed in normal mice using different
frequencies and routes of administration over wide dose ranges. In
particular, these studies focused on determining if the increase in
serum half-life and in vivo activity would confer the clinical
benefit of allowing for less frequent dosing. 
As has been shown for rHuEPO, NESP produced a dose-
dependent increase in the haematocrit of normal mice when
injected by the intravenous, intraperitoneal and subcutaneous
routes (Egrie et al, 1997). Initial experiments focused on
comparing the efficacy of the 2 molecules when administered
3 times per week. In the experiment shown in Figure 7, thrice-
weekly intravenous dosing with 1.25 mcg kg–1 of NESP increased
the haematocrit of mice to approximately 75% in 6 weeks;
however, a comparable haematocrit increase with rHuEPO at this
dosing frequency required 5.0 mcg kg–1. When the data from all
experiments were combined, NESP was determined to be approxi-
mately 3.6-fold more potent than rHuEPO when administered
three times per week by any route of administration. 
NESP can successfully increase the haematocrit of mice when
administered once per week (Figure 7). A once-weekly dose of
15 mcg kg–1 NESP produced a nearly identical biological response in
normal mice as did a thrice-weekly dose of 1.25 mcg kg–1
(3.75 mcg kg–1 total weekly dose). Thus, for NESP, an approximate
4-fold weekly dose increase is required to change from thrice-weekly
to once-weekly dosing in this animal model. It is important to note,
however, that in human clinical studies, there were no apparent
differences between once-weekly and thrice-weekly dosing with
NESP (Macdougall et al, 1998). The optimal weekly dose was the
same whether administered once per week or as 3 divided doses. The
differences observed between the small animal model, and human
clinical trials are presumably due to the differences in the erythroki-
netics and red blood cell lifespan of the 2 species. 
Once-weekly dosing with rHuEPO is far less efficient than
once-weekly dosing with NESP. As shown in Figure 7, once-
weekly dosing with 22.5 mcg kg–1 rHuEPO increased the
haematocrit by 7 points in 6 weeks, while a 2.5 mcg kg–1 dose
administered three times per week (7.5 mcg kg–1 total weekly
dose) increased the haematocrit by 22 points in the same time
period. Integration of the data from all experiments demonstrated
that for rHuEPO an approximate 15-fold weekly dose increase is
required to change from thrice-weekly to once-weekly dosing in
this animal model. 
When the efficacy of once-weekly dosing of NESP and rHuEPO
were compared, a striking difference in the potency of the 
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Figure 5 In vivo efficacy of rHuEPO (isoforms 9–14), 4-chain analogue, and
NESP. CD-1 mice (8–13/group) received an equimolar dose (2.5 mcg kg–1
of peptide) of rHuEPO (o), 4-chain analogue (x), or NESP (l), or vehicle
control (n), 3 times per week for 42 days by intraperitoneal injection. Each
point represents the group average haematocrit (± SD) for anti-rHuEPO
antibody-negative mice (see Figure 2) 
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Figure 6 Serum half-life of rHuEPO (isoforms 9–14), 4-chain analogue, and
NESP. The test molecules were iodinated and administered intravenously
into cannulated Sprague-Dawley rats (n = 10 for rHuEPO, n = 6/group for 
4-chain analogue and NESP). Blood samples were collected periodically and
the amount of ethanol-precipitable iodinated test compound remaining in the
serum was measured two molecules was observed. As seen in Figure 7, a 3.75 mcg kg–1
dose of NESP administered one time per week increased the
haematocrit by 12 points. In contrast, a 6-fold higher dose of
rHuEPO (22.5 mcg kg–1) increased the haematocrit by only 
7 points. When relative potency plots were constructed from all of
the data, NESP was found to be 13- to 14-fold more potent than
rHuEPO when each was administered once-weekly. 
As a consequence of the relative potency differences described
above, NESP administered once-weekly is as effective as the same
total weekly dose of rHuEPO given as 3 divided doses (Figure 8).
These experiments demonstrate that the same dose of NESP can
be administered less frequently than rHuEPO to obtain the same
biological response. Furthermore, dosing with NESP as infre-
quently as once every other week can still increase the haematocrit
of normal mice (data not shown). 
As expected from the pharmacokinetic differences between
NESP and rHuEPO, no one number can be used to express the
relative potency difference between the 2 molecules. The relative
potency of NESP and rHuEPO will necessarily change as a func-
tion of the dosing interval. Longer intervals between the adminis-
tration of doses will lead to a greater potency difference. Thus,
when each molecule is administered 3 times per week NESP is
approximately 3.6-fold more potent than rHuEPO; however, when
each molecule is administered once-weekly NESP is 13- to 14-
fold more potent. 
COMPARATIVE PHARMACOKINETICS OF NESP
AND EPOETIN ALFA IN DIALYSIS PATIENTS 
The first step in the clinical programme to determine if NESP is
both more potent than epoetin alfa and can be administered less
frequently, was to verify that NESP had a longer serum half-life in
patients. In a double-blind, randomized cross-over study, the
single-dose pharmacokinetics of epoetin alfa (100 U kg–1) and an
equimolar dose of NESP were compared after intravenous admin-
istration to 11 stable peritoneal dialysis patients (Macdougall et al,
1999). Serum levels of NESP and rHuEPO were determined at
regular intervals up to 96 hours after dosing by immunoassay. In
all patients, NESP had a longer terminal half-life than epoetin alfa
(Figure 9). The mean terminal half-life for NESP following intra-
venous injection was 26.3 hours, approximately 3-fold longer than
that determined for epoetin alfa (8.5 hours). There was no signifi-
cant difference in the volume of distribution for the 2 molecules.
This first study in man confirmed and extended the observations in
animal studies with NESP, demonstrating that due to its increased
sialic acid-containing carbohydrate content, NESP has a decreased
clearance and longer serum half-life than rHuEPO. 
Ongoing clinical studies are evaluating the safety and relative
efficacy of NESP as compared with epoetin alfa in different
patient groups. Since the amino acid sequence of NESP differs
at 5 amino acid positions from EPO, it is theoretically possible
that NESP could be immunogenic. If NESP antibodies were to
develop, they could be non-neutralizing (benign), or neutralizing,
rendering NESP ineffective. In addition, either the neutralizing or
non-neutralizing antibodies may cross-react with EPO. Due to this
theoretical, but real, concern, patients are being closely monitored
for the development of NESP antibodies in all clinical studies. 
However, several important features of NESP suggest that the
risk of immunogenicity may be minimal. One of the known func-
tions of carbohydrate in glycoproteins is to act as a molecular
shield, protecting the underlying polypeptide from the immune
8 JC Egrie and JK Browne 
British Journal of Cancer (2001) 84(Supplement 1), 3–10 © 2001 Cancer Research Campaign
85
80
75
70
65
60
55
50
45
40
H
a
e
m
a
t
o
c
r
i
t
 
(
%
)
01 0 2 0 3 0 4 0
NESP
rHuEPO
85
80
75
70
65
60
55
50
45
40
H
a
e
m
a
t
o
c
r
i
t
 
(
%
)
01 0 2 0 3 0 4 0
Day of study
mcg kg
–1
dose
–1
Total weekly
dose (mcg kg
–1)
1.25 TIW
15.0   QW
3.75
15.0
3.75 3.75 QW
Vehicle control
5.0   TIW
2.5   TIW
22.5   QW
Vehicle control
15.0
7.5
22.5
Figure 7 In vivo efficacy of NESP and rHuEPO administered three times
(TIW), or one time (QW) per week. CD-1 mice (n = 7/group) received
rHuEPO (open symbols), NESP (closed symbols), or vehicle control (n) 
three times per week (TIW, dashed lines), or one time per week (QW, solid
lines) at the indicated dose levels for 42 days by intravenous injection. Each
point represents the group average haematocrit (± SD) for the anti-rHuEPO
antibody-negative mice (see Figure 2). Both the dose/administration and the
total weekly dose are indicated on the graph 
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system (Skehel et al, 1984). Since the location of the 5 amino acid
differences between NESP and EPO is at or proximal to the carbo-
hydrate addition site, it is likely that these sites will be well
shielded from immune surveillance. The fact that the new carbo-
hydrate addition sites are distal to the receptor-binding site mini-
mizes the possibility that any antibodies that develop would
be neutralizing. Carbohydrate chains in themselves are rarely
immunogenic and since all of the oligosaccharide structures on
NESP are also found on epoetin, it is very unlikely that they will
be immunogenic. Results from preclinical studies provide support
for these considerations. In a mouse model, where the injection of
heterologous human proteins is expected to lead to antibody
formation, the incidence of seroconversion in NESP-treated
animals was no higher than for rHuEPO-treated animals.
Significantly, in all of the clinical trials to date, no patient has
developed antibodies to NESP. 
CONCLUSIONS 
NESP has been engineered to contain 5 N-linked carbohydrate
chains (2 more than rHuEPO). The additional carbohydrate affects
the biochemical and biological properties of NESP (Figure 4). Due
to the additional sialic acid-containing carbohydrate, NESP has
a slower serum clearance and, therefore, a longer half-life than
rHuEPO. The longer serum half-life increases the in vivo biolog-
ical activity and allows NESP to be administered less frequently
than rHuEPO. The safety and efficacy of NESP for use as a thera-
peutic for the treatment of anaemia and reduction in its incidence
is being evaluated in ongoing clinical trials. 
The development of NESP is an outgrowth of basic research
directed towards elucidating those structural features that control
the in vivo biological activity of EPO. It was discovered that the
pharmacokinetic properties of rHuEPO have a stronger influence
on in vivo activity than receptor affinity and that the serum clear-
ance of rHuEPO could be manipulated by changing the proportion
of sialic acid-containing carbohydrate. These observations may be
applicable for optimization of other protein therapeutics for
clinical use. 
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